{"id":390636,"date":"2025-09-14T16:39:11","date_gmt":"2025-09-14T16:39:11","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/390636\/"},"modified":"2025-09-14T16:39:11","modified_gmt":"2025-09-14T16:39:11","slug":"trois-nouveaux-membres-au-conseil-dadministration-du-montpellierain-medincell","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/390636\/","title":{"rendered":"Trois nouveaux membres au conseil d\u2019administration du montpelli\u00e9rain Medincell"},"content":{"rendered":"<p>La soci\u00e9t\u00e9 biopharmaceutique montpellieraine <a href=\"https:\/\/www.touleco.fr\/Medincell-lance-un-traitement-unique-contre-la-schizophrenie,43386\" class=\"spip_in\" target=\"_blank\" rel=\"noopener\">Medincell<\/a>, qui d\u00e9veloppe notamment de traitements contre la schizophr\u00e9nie et l\u2019ob\u00e9sit\u00e9, annonce la nomination de trois nouveaux membres ind\u00e9pendants au conseil d\u2019administration, les docteurs Sharon Mates, Charles Kunsch et Pascal Touchon.<\/p>\n<p>Sharon Mates est la cofondatrice et ancienne PDG d\u2019Intra-Cellular Therapies, une biotech sp\u00e9cialis\u00e9e dans le syst\u00e8me nerveux central, qui a d\u00e9velopp\u00e9 le m\u00e9dicament Caplyta avant d\u2019\u00eatre achet\u00e9e par Johnson &amp; Johnson pour 14,6 milliards de dollars en avril 2025. Charles Kunsch est un dirigeant exp\u00e9riment\u00e9 avec plus de 30 ans d\u2019exp\u00e9rience, qui a pilot\u00e9 des investissements dans des entreprises biotechnologiques innovantes. Pascal Touchon a plus de 40 ans d\u2019exp\u00e9rience \u00e0 des postes de direction dans l\u2019industrie biopharmaceutique au niveau international, notamment chez Novartis Oncology et Atara Biotherapeutics.<\/p>\n","protected":false},"excerpt":{"rendered":"La soci\u00e9t\u00e9 biopharmaceutique montpellieraine Medincell, qui d\u00e9veloppe notamment de traitements contre la schizophr\u00e9nie et l\u2019ob\u00e9sit\u00e9, annonce la nomination&hellip;\n","protected":false},"author":2,"featured_media":373637,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9599],"tags":[1111,11,52283,1777,674,1011,27,52284,2208,12,2680,25,71],"class_list":{"0":"post-390636","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-montpellier","8":"tag-actu","9":"tag-actualites","10":"tag-biotechnologies","11":"tag-eu","12":"tag-europe","13":"tag-fr","14":"tag-france","15":"tag-medincell","16":"tag-montpellier","17":"tag-news","18":"tag-occitanie","19":"tag-republique-francaise","20":"tag-sante"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115203641449838067","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/390636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=390636"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/390636\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/373637"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=390636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=390636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=390636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}